BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 7655385)

  • 1. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
    Kloosterman TC; Martens AC; van Bekkum DW; Hagenbeek A
    Bone Marrow Transplant; 1995 Apr; 15(4):583-90. PubMed ID: 7655385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
    Kloosterman TC; Tielemans MJ; Martens AC; van Bekkum DW; Hagenbeek A
    Bone Marrow Transplant; 1994 Jul; 14(1):15-22. PubMed ID: 7951103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
    Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
    Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
    Kloosterman TC; Martens AC; Osterwalder B; Hagenbeek A
    Bone Marrow Transplant; 1994 Dec; 14(6):965-73. PubMed ID: 7711675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
    Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
    Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
    Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
    Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S; Sado T; Kamisaku H; Nemoto K; Yoshida K
    Bone Marrow Transplant; 1994 Feb; 13(2):109-14. PubMed ID: 8205078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
    Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
    J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice].
    Xia YJ; Gao QP; Wan CC; Cheng FJ; Liu ZX; Guo RC
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):404-7. PubMed ID: 16251021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S; Kamisaku H; Sado T
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.